We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$37.8M
Cap. Flow
+$32.6M
Cap. Flow %
20.39%
Top 10 Hldgs %
54.86%
Holding
54
New
17
Increased
15
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$9.48M
2
XCUR icon
Exicure
XCUR
+$5.81M
3
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$4.75M
4
KALV
KalVista Pharmaceuticals
KALV
+$4.74M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$4.15M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$6.04M
2
PRTA icon
Prothena Corp
PRTA
+$5.55M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.94M
4
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$2.45M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 94.83%
2 Industrials 2.39%
3 Energy 1.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATIP
26
DELISTED
ATI Physical Therapy, Inc.
ATIP
$1.65M 1.03%
+3,466
New +$1.72M
MDT icon
27
Medtronic
MDT
$107B
$1.36M 0.85%
11,000
-9,088
-45% -$1.14M
IRTC icon
28
iRhythm Holdings
IRTC
$3.59B
$1.34M 0.84%
+20,200
New +$1.6M
CLLS
29
Cellectis
CLLS
$286M
$1.33M 0.83%
86,036
-51,864
-38% -$872K
OSCR icon
30
Oscar Health
OSCR
$8.5B
$1.18M 0.74%
55,000
-52,086
-49% -$1.25M
ALBO
31
CALL
DELISTED
Albireo Pharma Inc
ALBO
$1.16M 0.72%
+32,900
New +$1.07M
EVH icon
32
Evolent Health
EVH
$475M
$1.1M 0.69%
+52,023
New +$1.04M
CLOV icon
33
Clover Health Investments
CLOV
$2.28B
$1.05M 0.66%
+79,100
New +$777K
AKU
34
DELISTED
Akumin Inc
AKU
$1.03M 0.65%
327,680
-101,381
-24% -$305K
AUPH icon
35
CALL
Aurinia Pharmaceuticals
AUPH
$1.97B
$871K 0.54%
+67,200
New +$856K
NUVB icon
36
Nuvation Bio
NUVB
$2.24B
$854K 0.53%
+91,694
New +$1.05M
SIOX
37
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$699K 0.44%
256,115
+50,215
+24% +$125K
ONCR
38
DELISTED
Oncorus, Inc.
ONCR
$690K 0.43%
50,000
-20,807
-29% -$321K
OPCH icon
39
Option Care Health
OPCH
$3.4B
$610K 0.38%
+27,875
New +$537K
ASMB icon
40
Assembly Biosciences
ASMB
$506M
$578K 0.36%
12,424
+7,716
+164% +$382K
XFOR icon
41
X4 Pharmaceuticals
XFOR
$363M
$571K 0.36%
+2,927
New +$736K
OKUR
42
OnKure Therapeutics
OKUR
$166M
$513K 0.32%
+5,493
New +$613K
APTO
43
DELISTED
Aptose Biosciences, Inc.
APTO
$442K 0.28%
296
-37
-11% -$80.6K
ORGO icon
44
Organogenesis Holdings
ORGO
$308M
$417K 0.26%
25,100
+9,868
+65% +$184K
CANO
45
DELISTED
Cano Health, Inc.
CANO
$281K 0.18%
+232
New +$313K
ADMA icon
46
ADMA Biologics
ADMA
$1.92B
$184K 0.12%
115,100
-382,742
-77% -$673K
BAX icon
47
Baxter International
BAX
$11.6B
– –
-5,800
Closed -$489K
BEAM icon
48
Beam Therapeutics
BEAM
$2.58B
– –
-17,000
Closed -$1.36M
BMY icon
49
Bristol-Myers Squibb
BMY
$127B
– –
-95,600
Closed -$6.04M
SLDB icon
50
Solid Biosciences
SLDB
$771M
– –
-21,340
Closed -$1.77M
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2021 Portfolio in Review

As of Q2 2021, Prosight Management held 54 positions worth $160M, up 31% from $122M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $32.6M of net new capital in Q2 2021, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Haemonetics: 134,000 shares worth $8.93M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Industrials and Energy.

On the sell side, the largest reduction was Prothena Corp, an estimated $5.55M trimmed.

  • Prosight Management's largest Q2 2021 buy was Haemonetics: 134,000 shares worth $8.93M.
  • Prosight Management added most to Exicure in Q2 2021, an estimated $5.81M increase.
  • Prosight Management's biggest Q2 2021 reduction was Prothena Corp, cutting an estimated $5.55M.
  • Prosight Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $6.04M.
  • Prosight Management's ten largest holdings make up 55% of its $160M portfolio in Q2 2021.
  • Prosight Management opened 17 new positions and closed 8 in Q2 2021.
  • Prosight Management's portfolio value rose 31% quarter-over-quarter to $160M.

Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.